Biodesix Q1 revenue $18M (+21% YoY); revises FY2025 guidance to $80-85M

BIODESIX INC

2025-Q1 EPS reported -$0.08 revenue$17,958,000

Total Q1 2025 revenue $18.0M (+21% YoY); diagnostic testing $16.3M (+18%), development services $1.7M (+61%).
Gross margin 79.4% (vs 78.6%); net loss $11.1M (improved 18% YoY); Adjusted EBITDA loss $6.2M (improved 11%).
FY2025 revenue guidance revised to $80-85M due to ~1-quarter delay in sales expansion; still expects Q4 2025 Adj. EBITDA positivity.
Drew $10M Tranche C from Perceptive Advisors loan, pro forma cash $27.6M; warrants exercise price modified to $0.4191/share.
Operating expenses $23.4M (+3% YoY): R&D up $0.9M, SG&A down 1%; non-cash stock comp fell to $1.0M from $2.6M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.